{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:35:46Z","timestamp":1789079746866,"version":"build-2803163510"},"reference-count":150,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.dld.2020.08.031","type":"journal-article","created":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T03:36:04Z","timestamp":1599536164000},"page":"171-182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Update on gastroenteropancreatic neuroendocrine tumors"],"prefix":"10.1016","volume":"53","author":[{"given":"Valentina","family":"Andreasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Partelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Muffatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco F.","family":"Manzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Capurso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Falconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2020.08.031_bib0001","first-page":"471","article-title":"Gastroenteropancreatic Neuroendocrine Tumors","volume":"68","author":"Cives","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.dld.2020.08.031_bib0002","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1200\/JOP.2010.000098","article-title":"Multidisciplinary reference centers: the care of neuroendocrine tumors","volume":"6","author":"Singh","year":"2010","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.dld.2020.08.031_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000442207","article-title":"Trends in incidence of neuroendocrine neoplasms in norway: a report of 16,075 cases from 1993 through 2010","volume":"104","author":"Boyar Cetinkaya","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2020.08.031_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2019.101598","article-title":"Epidemiological trends of neuroendocrine tumours over three decades in Queensland, Australia","volume":"63","author":"Wyld","year":"2019","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.dld.2020.08.031_bib0005","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.dld.2020.08.031_bib0006","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/cncr.29099","article-title":"Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes","volume":"121","author":"Hallet","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.dld.2020.08.031_bib0007","series-title":"Histological typing of endocrine tumors. WHO international histological classification of tumors","author":"Solcia","year":"2000"},{"key":"10.1016\/j.dld.2020.08.031_bib0008","series-title":"Pathol. Genet. tumors Endocr. organs","first-page":"177","article-title":"Pancreatic endocrine tumors: introduction","author":"Heitz","year":"2004"},{"key":"10.1016\/j.dld.2020.08.031_bib0009","doi-asserted-by":"crossref","first-page":"R153","DOI":"10.1530\/ERC-13-0125","article-title":"Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature","volume":"21","author":"Fraenkel","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.dld.2020.08.031_bib0010","doi-asserted-by":"crossref","first-page":"R163","DOI":"10.1530\/ERC-12-0024","article-title":"Neuroendocrine tumor disease: an evolving landscape","volume":"19","author":"Frilling","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.dld.2020.08.031_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ecl.2010.12.005","article-title":"The epidemiology of gastroenteropancreatic neuroendocrine tumors","volume":"40","author":"Lawrence","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.dld.2020.08.031_bib0012","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ejso.2018.01.082","article-title":"Incidence and survival trends for gastric neuroendocrine neoplasms: An analysis of 3523 patients in the SEER database","volume":"44","author":"Cao","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.dld.2020.08.031_bib0013","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/2050640619865113","article-title":"Change in incidence, characteristics and management of colorectal neuroendocrine tumours in the Netherlands in the last decade","volume":"8","author":"Kooyker","year":"2020","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.dld.2020.08.031_bib0014","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1245\/s10434-013-3005-7","article-title":"Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size","volume":"20","author":"Kuo","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.dld.2020.08.031_bib0015","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/cncr.32793","article-title":"Continued increasing incidence of malignant appendiceal tumors in Canada and the United States: A population-based study","volume":"126","author":"Singh","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.dld.2020.08.031_bib0016","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.diabres.2012.08.007","article-title":"Asymptomatic insulinoma: a case report and autopsy series","volume":"98","author":"Kishi","year":"2012","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.dld.2020.08.031_bib0017","doi-asserted-by":"crossref","DOI":"10.1159\/000499606","article-title":"Is the real prevalence of pancreatic neuroendocrine tumors underestimated? A retrospective study on a large series of pancreatic specimens","author":"Partelli","year":"2019","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2020.08.031_bib0018","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000448431","article-title":"Professional practices and diagnostic issues in neuroendocrine tumour pathology: results of a prospective one-year survey among French pathologists (the PRONET Study)","volume":"105","author":"Scoazec","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2020.08.031_bib0019","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-15-0119","article-title":"Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms","volume":"22","author":"Heetfeld","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.dld.2020.08.031_bib0020","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/annonc\/mds276","article-title":"Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study","volume":"24","author":"Sorbye","year":"2013","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.dld.2020.08.031_bib0021","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000443168","article-title":"ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms","volume":"103","author":"Delle Fave","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"Suppl 3","key":"10.1016\/j.dld.2020.08.031_bib0022","doi-asserted-by":"crossref","first-page":"S742","DOI":"10.1245\/s10434-015-4620-2","article-title":"Surgical management of small bowel neuroendocrine tumors: specific requirements and their impact on staging and prognosis","volume":"22","author":"Pasquer","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.dld.2020.08.031_bib0023","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.surg.2016.05.055","article-title":"Identification of primary tumors in patients presenting with metastatic gastroenteropancreatic neuroendocrine tumors","volume":"161","author":"Keck","year":"2017","journal-title":"Surgery"},{"key":"10.1016\/j.dld.2020.08.031_bib0024","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000464292","article-title":"ENETS consensus guidelines for standard of care in neuroendocrine tumours: surgery for small intestinal and pancreatic neuroendocrine tumours","volume":"105","author":"Partelli","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2020.08.031_bib0025","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1200\/JCO.2005.01.013","article-title":"Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging","volume":"23","author":"Dromain","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2020.08.031_bib0026","first-page":"473","article-title":"Digestive neuroendocrine neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)","volume":"52","author":"de Mestier","year":"2020","journal-title":"Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver"},{"key":"10.1016\/j.dld.2020.08.031_bib0027","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1159\/000446369","article-title":"Impact of liver and whole-body diffusion-weighted MRI for neuroendocrine tumors on patient management: a pilot study","volume":"104","author":"Moryoussef","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2020.08.031_bib0028","doi-asserted-by":"crossref","DOI":"10.1159\/000443166","article-title":"ENETS consensus guidelines update for colorectal neuroendocrine neoplasms","author":"Ramage","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2020.08.031_bib0029","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000499172","article-title":"Pancreatic neuroendocrine tumours: the role of endoscopic ultrasound biopsy in diagnosis and grading based on the WHO 2017 classification","volume":"37","author":"Di Leo","year":"2019","journal-title":"Dig Dis"},{"key":"10.1016\/j.dld.2020.08.031_bib0030","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000382062","article-title":"Endoscopy and endoscopic ultrasound in assessing and managing neuroendocrine neoplasms","volume":"44","author":"O'Toole","year":"2015","journal-title":"Front Horm Res"},{"key":"10.1016\/j.dld.2020.08.031_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2019.101293","article-title":"Endoscopic, transanal, laparoscopic, and transabdominal management of rectal neuroendocrine tumors","volume":"33","author":"de Mestier","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.dld.2020.08.031_bib0032","doi-asserted-by":"crossref","first-page":"347","DOI":"10.14740\/gr937w","article-title":"Carcinoids and capsules: a case series highlighting the utility of capsule endoscopy in patients with small bowel carcinoids","volume":"10","author":"Noujaim","year":"2017","journal-title":"Gastroenterol Res"},{"key":"10.1016\/j.dld.2020.08.031_bib0033","series-title":"WHO classification of tumours. digestive system tumours","year":"2019"},{"key":"10.1016\/j.dld.2020.08.031_bib0034","series-title":"WHO classification of tumours of endocrine organs","year":"2017"},{"key":"10.1016\/j.dld.2020.08.031_bib0035","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1007\/s00330-017-4803-2","article-title":"Evaluation of (68)Ga-DOTATOC PET\/MRI for whole-body staging of neuroendocrine tumours in comparison with (68)Ga-DOTATOC PET\/CT","volume":"27","author":"Sawicki","year":"2017","journal-title":"Eur Radiol"},{"key":"10.1016\/j.dld.2020.08.031_bib0036","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000443171","article-title":"ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors","volume":"103","author":"Falconi","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2020.08.031_bib0037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MPA.0000000000001454","article-title":"The North American neuroendocrine tumor society consensus paper on the surgical management of pancreatic neuroendocrine tumors","volume":"49","author":"Howe","year":"2020","journal-title":"Pancreas"},{"key":"10.1016\/j.dld.2020.08.031_bib0038","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.2015.64.0987","article-title":"Prospective Study of 68Ga-DOTATATE positron emission tomography\/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites","volume":"34","author":"Sadowski","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2020.08.031_bib0039","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2967\/jnumed.115.166017","article-title":"The impact of 68Ga-DOTATATE PET\/CT imaging on management of patients with neuroendocrine tumors: experience from a national referral center in the United Kingdom","volume":"57","author":"Skoura","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.dld.2020.08.031_bib0040","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/jso.25812","article-title":"Impact of initial imaging with gallium-68 dotatate PET\/CT on diagnosis and management of patients with neuroendocrine tumors","volume":"121","author":"Crown","year":"2020","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.dld.2020.08.031_bib0041","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11091332","article-title":"Bone metastases in neuroendocrine neoplasms: from pathogenesis to clinical management","volume":"11","author":"Altieri","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.dld.2020.08.031_bib0042","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1159\/000441604","article-title":"Is there an additional value of using somatostatin receptor subtype 2a immunohistochemistry compared to somatostatin receptor scintigraphy uptake in predicting gastroenteropancreatic neuroendocrine tumor response?","volume":"103","author":"van Adrichem","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2020.08.031_bib0043","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1148\/rg.352140164","article-title":"Somatostatin receptor imaging with 68Ga DOTATATE PET\/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation","volume":"35","author":"Hofman","year":"2015","journal-title":"Radiographics"},{"key":"10.1016\/j.dld.2020.08.031_bib0044","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-19-0476","article-title":"Innovative imaging of insulinoma: the end of sampling? A review","author":"Christ","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.dld.2020.08.031_bib0045","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00259-003-1184-3","article-title":"Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting","volume":"30","author":"Reubi","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.dld.2020.08.031_bib0046","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1007\/s00259-018-4101-5","article-title":"Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET\/CT, SPECT\/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study","volume":"45","author":"Antwi","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.dld.2020.08.031_bib0047","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000368609","article-title":"The role of combined Ga-DOTANOC and (18)FDG PET\/CT in the management of patients with pancreatic neuroendocrine tumors","volume":"100","author":"Partelli","year":"2014","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2020.08.031_bib0048","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2340389","article-title":"Clinical and Prognostic Value of PET\/CT Imaging with Combination of (68)Ga-DOTATATE and (18)F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms","volume":"2018","author":"Zhang","year":"2018","journal-title":"Contrast Media Mol Imaging"},{"key":"10.1016\/j.dld.2020.08.031_bib0049","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00595-018-1703-2","article-title":"Clinical role of fludeoxyglucose (18F) positron emission tomography\/computed tomography ((18)F-FDG PET\/CT) in patients with pancreatic neuroendocrine tumors","volume":"49","author":"Matsumoto","year":"2019","journal-title":"Surg Today"},{"key":"10.1016\/j.dld.2020.08.031_bib0050","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1634\/theoncologist.2017-0278","article-title":"Clinical usefulness of (18)F-fluorodeoxyglucose positron emission tomography in the diagnostic algorithm of advanced entero-pancreatic neuroendocrine neoplasms","volume":"23","author":"Rinzivillo","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.dld.2020.08.031_bib0051","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1530\/ERC-17-0269","article-title":"Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame","volume":"25","author":"Marotta","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.dld.2020.08.031_bib0052","doi-asserted-by":"crossref","first-page":"e435","DOI":"10.1016\/S1470-2045(15)00186-2","article-title":"Consensus on biomarkers for neuroendocrine tumour disease","volume":"16","author":"Oberg","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2020.08.031_bib0053","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.pan.2018.11.005","article-title":"Association between preoperative Vasostatin-1 and pathological features of aggressiveness in localized nonfunctioning pancreatic neuroendocrine tumors (NF-PanNET)","volume":"19","author":"Andreasi","year":"2019","journal-title":"Pancreatology"},{"key":"10.1016\/j.dld.2020.08.031_bib0054","article-title":"Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumours: An ENETS Centre of Excellence Experience","author":"Malczewska","year":"2020","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2020.08.031_bib0055","article-title":"Circulating neuroendocrine gene transcripts (NETest): a postoperative strategy for early identification of the efficacy of radical surgery for pancreatic neuroendocrine tumors","author":"Partelli","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.dld.2020.08.031_bib0056","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00259-019-04601-3","article-title":"PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest","volume":"47","author":"Bodei","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.dld.2020.08.031_bib0057","doi-asserted-by":"crossref","first-page":"6817","DOI":"10.3748\/wjg.v22.i30.6817","article-title":"Management of gastric and duodenal neuroendocrine tumors","volume":"22","author":"Sato","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2020.08.031_bib0058","doi-asserted-by":"crossref","first-page":"8687","DOI":"10.3748\/wjg.v19.i46.8687","article-title":"Metastatic type 1 gastric carcinoid: a real threat or just a myth?","volume":"19","author":"Grozinsky-Glasberg","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2020.08.031_bib0059","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.dld.2019.04.016","article-title":"Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: A multicentre retrospective study","volume":"51","author":"Panzuto","year":"2019","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2020.08.031_bib0060","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000489902","article-title":"Prognostic evaluations tailored to specific gastric neuroendocrine neoplasms: analysis of 200 cases with extended follow-up","volume":"107","author":"Vanoli","year":"2018","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2020.08.031_bib0061","doi-asserted-by":"crossref","DOI":"10.1007\/s11154-018-9445-4","article-title":"How should incidental NEN of the pancreas and gastrointestinal tract be followed?","author":"Ariotti","year":"2018","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.dld.2020.08.031_bib0062","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000329043","article-title":"Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate","volume":"95","author":"Merola","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2020.08.031_bib0063","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s12020-017-1355-9","article-title":"Management of gastric neuro-endocrine tumours in a large French national cohort (GTE)","volume":"57","author":"Manfredi","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.dld.2020.08.031_bib0064","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/cen.14055","article-title":"Recurrence and metastatic potential in Type 1 gastric neuroendocrine neoplasms","volume":"91","author":"Daskalakis","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.dld.2020.08.031_bib0065","doi-asserted-by":"crossref","first-page":"8703","DOI":"10.3748\/wjg.v19.i46.8703","article-title":"Long-term follow up of endoscopic resection for type 3 gastric NET","volume":"19","author":"Kwon","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2020.08.031_bib0066","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/bjs.10901","article-title":"Clinicopathological features and outcome of type 3 gastric neuroendocrine tumours","volume":"105","author":"Min","year":"2018","journal-title":"Br J Surg"},{"key":"10.1016\/j.dld.2020.08.031_bib0067","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s11605-013-2365-4","article-title":"Clinical outcomes for neuroendocrine tumors of the duodenum and ampulla of Vater: a population-based study","volume":"18","author":"Randle","year":"2014","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.dld.2020.08.031_bib0068","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000444803","article-title":"Four Neuroendocrine Tumor Types and Neuroendocrine Carcinoma of the Duodenum: Analysis of 203 Cases","volume":"104","author":"Vanoli","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2020.08.031_bib0069","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1245\/s10434-018-6673-5","article-title":"Heterogeneity of duodenal neuroendocrine tumors: an italian multi-center experience","volume":"25","author":"Massironi","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.dld.2020.08.031_bib0070","doi-asserted-by":"crossref","first-page":"e16154","DOI":"10.1097\/MD.0000000000016154","article-title":"Comparisons of therapeutic outcomes in patients with nonampullary duodenal neuroendocrine tumors (NADNETs): A multicenter retrospective study","volume":"98","author":"Lee","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.dld.2020.08.031_bib0071","doi-asserted-by":"crossref","first-page":"e15885","DOI":"10.1097\/MD.0000000000015885","article-title":"Risk factors for lymph node metastasis in duodenal neuroendocrine tumors: A retrospective, single-center study","volume":"98","author":"Park","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.dld.2020.08.031_bib0072","article-title":"Surgical resection for duodenal neuroendocrine neoplasia: Outcome, prognostic factors and risk of metastases","author":"Niessen","year":"2020","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.dld.2020.08.031_bib0073","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/bjs.10312","article-title":"Systematic review of active surveillance versus surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms","volume":"104","author":"Partelli","year":"2017","journal-title":"Br J Surg"},{"key":"10.1016\/j.dld.2020.08.031_bib0074","article-title":"Resection versus observation of small asymptomatic nonfunctioning pancreatic neuroendocrine tumors","author":"Barenboim","year":"2019","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.dld.2020.08.031_bib0075","article-title":"Management of small asymptomatic nonfunctioning pancreatic neuroendocrine tumors: Limitations to apply guidelines into real life","author":"Partelli","year":"2019","journal-title":"Surg (United States)"},{"key":"10.1016\/j.dld.2020.08.031_bib0076","article-title":"Surgery versus surveillance for well\u2010differentiated, nonfunctional pancreatic neuroendocrine tumors: an 11\u2010year analysis of the national cancer database","author":"Assi","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.dld.2020.08.031_bib0077","article-title":"A survival analysis of patients with localized, asymptomatic pancreatic neuroendocrine tumors: no surgical survival benefit when examining appropriately selected outcomes","author":"Powers","year":"2019","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.dld.2020.08.031_bib0078","doi-asserted-by":"crossref","DOI":"10.1007\/s00268-018-4751-2","article-title":"Implementation of current ENETS guidelines for surgery of small (\u22642 cm) pancreatic neuroendocrine neoplasms in the german surgical community: an analysis of the prospective DGAV StuDoQ|Pancreas registry","author":"Mintziras","year":"2019","journal-title":"World J Surg"},{"key":"10.1016\/j.dld.2020.08.031_bib0079","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.dld.2019.01.008","article-title":"The size of well differentiated pancreatic neuroendocrine tumors correlates with Ki67 proliferative index and is not associated with age","volume":"51","author":"Partelli","year":"2019","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2020.08.031_bib0080","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.pan.2018.08.004","article-title":"Endoscopic ultrasound appearance of pancreatic serotonin-staining neuroendocrine neoplasms","volume":"18","author":"Massironi","year":"2018","journal-title":"Pancreatology"},{"key":"10.1016\/j.dld.2020.08.031_bib0081","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.humpath.2016.05.023","article-title":"Ileal \u201ccarcinoid\u201d tumors-small size belies deadly intent: high rate of nodal metastasis in tumors <\/=1 cm in size","volume":"56","author":"Walsh","year":"2016","journal-title":"Hum Pathol"},{"key":"10.1016\/j.dld.2020.08.031_bib0082","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/SLA.0000000000002736","article-title":"Current management and predictive factors of lymph node metastasis of appendix neuroendocrine tumors: a national study from the french group of endocrine tumors (GTE)","volume":"270","author":"Rault-Petit","year":"2019","journal-title":"Ann Surg"},{"key":"10.1016\/j.dld.2020.08.031_bib0083","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000443165","article-title":"ENETS consensus guidelines for neuroendocrine neoplasms of the appendix (excluding goblet cell carcinomas)","volume":"103","author":"Pape","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2020.08.031_bib0084","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/000313481808400525","article-title":"Colon and rectal neuroendocrine tumors: are they really one disease? a single-institution experience over 15 years","volume":"84","author":"Broecker","year":"2018","journal-title":"Am Surg"},{"key":"10.1016\/j.dld.2020.08.031_bib0085","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1245\/s10434-019-07848-0","article-title":"Grade is a dominant risk factor for metastasis in patients with rectal neuroendocrine tumors","volume":"27","author":"Folkert","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.dld.2020.08.031_bib0086","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/jso.25679","article-title":"A novel preoperative risk score to predict lymph node positivity for rectal neuroendocrine tumors: An NCDB analysis to guide operative technique","volume":"120","author":"Gamboa","year":"2019","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.dld.2020.08.031_bib0087","doi-asserted-by":"crossref","first-page":"9142","DOI":"10.3748\/wjg.v21.i30.9142","article-title":"Full-thickness excision using transanal endoscopic microsurgery for treatment of rectal neuroendocrine tumors","volume":"21","author":"Chen","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2020.08.031_bib0088","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.amjsurg.2018.12.057","article-title":"Gastric carcinoids: Does type of surgery or tumor affect survival?","volume":"217","author":"Crown","year":"2019","journal-title":"Am J Surg"},{"key":"10.1016\/j.dld.2020.08.031_bib0089","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1007\/s11605-017-3448-4","article-title":"Duodenal and ampullary carcinoid tumors: size predicts necessity for lymphadenectomy","volume":"21","author":"Dogeas","year":"2017","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.dld.2020.08.031_bib0090","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/jso.25753","article-title":"Duodenal neuroendocrine tumors: Impact of tumor size and total number of lymph nodes examined","volume":"120","author":"Zhang","year":"2019","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.dld.2020.08.031_bib0091","doi-asserted-by":"crossref","DOI":"10.1097\/SLA.0000000000003461","article-title":"A novel validated recurrence risk score to guide a pragmatic surveillance strategy after resection of pancreatic neuroendocrine tumors: an international study of 1006 patients","author":"Zaidi","year":"2019","journal-title":"Ann Surg"},{"key":"10.1016\/j.dld.2020.08.031_bib0092","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1097\/SLA.0000000000002123","article-title":"A new scoring system to predict recurrent disease in grade 1 and 2 nonfunctional pancreatic neuroendocrine tumors","volume":"267","author":"Genc","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.dld.2020.08.031_bib0093","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1001\/jamasurg.2013.3376","article-title":"Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs)","volume":"148","author":"Partelli","year":"2013","journal-title":"JAMA Surg"},{"key":"10.1016\/j.dld.2020.08.031_bib0094","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2018.03.005","article-title":"The number of positive nodes accurately predicts recurrence after pancreaticoduodenectomy for nonfunctioning neuroendocrine neoplasms","volume":"44","author":"Partelli","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.dld.2020.08.031_bib0095","article-title":"New nodal staging for primary pancreatic neuroendocrine tumors: a multi-institutional and national data analysis","author":"Zhang","year":"2019","journal-title":"Ann Surg"},{"key":"10.1016\/j.dld.2020.08.031_bib0096","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1245\/s10434-019-07367-y","article-title":"Defining the role of lymphadenectomy for pancreatic neuroendocrine tumors: an eight-institution study of 695 patients from the US neuroendocrine tumor study group","volume":"26","author":"Lopez-Aguiar","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.dld.2020.08.031_bib0097","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/j.amjsurg.2009.02.017","article-title":"Middle-preserving pancreatectomy for multicentric body-sparing lesions of the pancreas","volume":"198","author":"Partelli","year":"2009","journal-title":"Am J Surg"},{"key":"10.1016\/j.dld.2020.08.031_bib0098","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8101611","article-title":"Long-term pancreatic functional impairment after surgery for neuroendocrine neoplasms","volume":"8","author":"Andreasi","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.dld.2020.08.031_bib0099","doi-asserted-by":"crossref","DOI":"10.1016\/j.hpb.2015.11.003","article-title":"Thirty-day outcomes underestimate endocrine and exocrine insufficiency after pancreatic resection","author":"Lim","year":"2016","journal-title":"HPB"},{"key":"10.1016\/j.dld.2020.08.031_bib0100","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/MPA.0000000000000846","article-title":"The surgical management of small bowel neuroendocrine tumors: consensus guidelines of the North American neuroendocrine tumor society","volume":"46","author":"Howe","year":"2017","journal-title":"Pancreas"},{"key":"10.1016\/j.dld.2020.08.031_bib0101","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1159\/000441423","article-title":"Toward a preoperative classification of lymph node metastases in patients with small intestinal neuroendocrine tumors in the era of intestinal-sparing surgery","volume":"103","author":"Lardiere-Deguelte","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2020.08.031_bib0102","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s00268-013-1918-8","article-title":"Resection of at-risk mesenteric lymph nodes is associated with improved survival in patients with small bowel neuroendocrine tumors","volume":"37","author":"Landry","year":"2013","journal-title":"World J Surg"},{"key":"10.1016\/j.dld.2020.08.031_bib0103","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1001\/jamasurg.2018.3865","article-title":"Prognostic role of lymph node positivity and number of lymph nodes needed for accurately staging small-bowel neuroendocrine tumors","volume":"154","author":"Zaidi","year":"2019","journal-title":"JAMA Surg"},{"key":"10.1016\/j.dld.2020.08.031_bib0104","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/SLA.0000000000002939","article-title":"Morphological factors related to nodal metastases in neuroendocrine tumors of the appendix: a multicentric retrospective study","volume":"271","author":"Brighi","year":"2020","journal-title":"Ann Surg"},{"key":"10.1016\/j.dld.2020.08.031_bib0105","doi-asserted-by":"crossref","unstructured":"Ricci C, Ingaldi C, Alberici L, Brighi N, Santini D, Mosconi C, et al. Histopathological diagnosis of appendiceal neuroendocrine neoplasms: when to perform a right hemicolectomy? A systematic review and meta-analysis. Endocrine2019:1\u20137. doi:10.1007\/s12020-019-01984-z.","DOI":"10.1007\/s12020-019-01984-z"},{"key":"10.1016\/j.dld.2020.08.031_bib0106","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s12020-019-02072-y","article-title":"The risk of lymph node metastases and their impact on survival in patients with appendiceal neuroendocrine neoplasms: a systematic review and meta-analysis of adult and paediatric patients","volume":"67","author":"Daskalakis","year":"2020","journal-title":"Endocrine"},{"key":"10.1016\/j.dld.2020.08.031_bib0107","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000335594","article-title":"ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms","volume":"95","author":"Caplin","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2020.08.031_bib0108","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1245\/s10434-012-2746-z","article-title":"Neuroendocrine tumors of the colon and rectum: prognostic relevance and comparative performance of current staging systems","volume":"20","author":"Chagpar","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.dld.2020.08.031_bib0109","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1245\/s10434-019-07327-6","article-title":"Colon neuroendocrine tumors: a new lymph node staging classification","volume":"26","author":"Fields","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.dld.2020.08.031_bib0110","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/jso.25307","article-title":"New lymph node staging for rectal neuroendocrine tumors","volume":"119","author":"Fields","year":"2019","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.dld.2020.08.031_bib0111","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s11605-016-3128-9","article-title":"Obturator canal lymph node metastasis from rectal carcinoid tumors: total mesorectal excision may be insufficient","volume":"20","author":"Wang","year":"2016","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.dld.2020.08.031_bib0112","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/DCR.0000000000000745","article-title":"Short- and long-term outcomes of laparoscopic total mesenteric excision for neuroendocrine tumors of the rectum","volume":"60","author":"Takatsu","year":"2017","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.dld.2020.08.031_bib0113","article-title":"Outcomes after distal pancreatectomy for neuroendocrine neoplasms: a retrospective comparison between minimally invasive and open approach using propensity score weighting","author":"Partelli","year":"2020","journal-title":"Surg Endosc"},{"key":"10.1016\/j.dld.2020.08.031_bib0114","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/17474124.2017.1253473","article-title":"Systematic review and meta-analysis on laparoscopic pancreatic resections for neuroendocrine neoplasms (PNENs)","volume":"11","author":"Tamburrino","year":"2017","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2020.08.031_bib0115","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/jso.25481","article-title":"Minimally invasive versus open distal pancreatectomy for pancreatic neuroendocrine tumors: An analysis from the U.S. neuroendocrine tumor study group","volume":"120","author":"Zhang","year":"2019","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.dld.2020.08.031_bib0116","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12893-017-0301-3","article-title":"Robotic versus laparoscopic distal pancreatectomy: an up-to-date meta-analysis","volume":"17","author":"Guerrini","year":"2017","journal-title":"BMC Surg"},{"key":"10.1016\/j.dld.2020.08.031_bib0117","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00423-019-01786-x","article-title":"Short-term and long-term outcomes after robot-assisted versus laparoscopic distal pancreatectomy for pancreatic neuroendocrine tumors (pNETs): a multicenter comparative study","volume":"404","author":"Alfieri","year":"2019","journal-title":"Langenbeck's Arch Surg"},{"key":"10.1016\/j.dld.2020.08.031_bib0118","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.surg.2015.09.012","article-title":"Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters","volume":"159","author":"Crippa","year":"2016","journal-title":"Surgery"},{"key":"10.1016\/j.dld.2020.08.031_bib0119","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s00268-012-1893-5","article-title":"Long-term outcome of laparoscopic surgery for pancreatic neuroendocrine tumors","volume":"37","author":"Haugvik","year":"2013","journal-title":"World J Surg"},{"key":"10.1016\/j.dld.2020.08.031_bib0120","article-title":"Surgery with radical intent: is there an indication for G3 neuroendocrine neoplasms?","author":"Merola","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.dld.2020.08.031_bib0121","doi-asserted-by":"crossref","DOI":"10.1245\/s10434-019-07252-8","article-title":"Surgery for pancreatic neuroendocrine tumor G3 and carcinoma G3 should be considered separately","author":"Yoshida","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.dld.2020.08.031_bib0122","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjsurg.2020.03.009","article-title":"Radical intended surgery for highly selected stage IV neuroendocrine neoplasms G3","author":"Merola","year":"2020","journal-title":"Am J Surg"},{"key":"10.1016\/j.dld.2020.08.031_bib0123","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","article-title":"ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2020.08.031_bib0124","doi-asserted-by":"crossref","DOI":"10.1016\/j.hpb.2017.10.014","article-title":"A Systematic review and meta-analysis on the role of palliative primary resection for pancreatic neuroendocrine neoplasm with liver metastases","volume":"20","author":"Partelli","year":"2018","journal-title":"HPB"},{"key":"10.1016\/j.dld.2020.08.031_bib0125","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.surg.2018.09.006","article-title":"Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors","volume":"165","author":"Tierney","year":"2019","journal-title":"Surgery"},{"key":"10.1016\/j.dld.2020.08.031_bib0126","doi-asserted-by":"crossref","DOI":"10.1245\/s10434-016-5550-3","article-title":"Resection of the primary tumor followed by peptide receptor radionuclide therapy as upfront strategy for the treatment of G1\u2013G2 pancreatic neuroendocrine tumors with unresectable liver metastases","author":"Bertani","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.dld.2020.08.031_bib0127","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.surg.2015.05.040","article-title":"Liver-directed surgery of neuroendocrine metastases: what is the optimal strategy?","volume":"159","author":"Maxwell","year":"2016","journal-title":"Surgery"},{"key":"10.1016\/j.dld.2020.08.031_bib0128","article-title":"Local treatment for focal progression in metastatic neuroendocrine tumors","author":"Al-Toubah","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.dld.2020.08.031_bib0129","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1111\/ajt.13831","article-title":"The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors","volume":"16","author":"Mazzaferro","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.dld.2020.08.031_bib0130","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1530\/ERC-15-0490","article-title":"Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study","volume":"23","author":"Caplin","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.dld.2020.08.031_bib0131","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000443612","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival","volume":"104","author":"Rinke","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2020.08.031_bib0132","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000475526","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues","volume":"105","author":"Hicks","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2020.08.031_bib0133","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-term efficacy, survival, and safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.dld.2020.08.031_bib0134","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2020.08.031_bib0135","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177lu-dotatate for midgut neuroendocrine tumors","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.dld.2020.08.031_bib0136","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1186\/s12885-019-6000-y","article-title":"Salvage PRRT with (177)Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival","volume":"19","author":"Rudisile","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.dld.2020.08.031_bib0137","article-title":"Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms","author":"Partelli","year":"2018","journal-title":"Surg (United States)"},{"key":"10.1016\/j.dld.2020.08.031_bib0138","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: systemic therapy-biotherapy and novel targeted agents","author":"Pavel","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2020.08.031_bib0139","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2020.08.031_bib0140","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.dld.2020.08.031_bib0141","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2020.08.031_bib0142","doi-asserted-by":"crossref","DOI":"10.1159\/000473892","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: systemic therapy-chemotherapy","author":"Garcia-Carbonero","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2020.08.031_bib0143","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cncr.25425","article-title":"First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas","volume":"117","author":"Strosberg","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.dld.2020.08.031_bib0144","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12010206","article-title":"Outcomes of capecitabine and temozolomide (CAPTEM) in advanced neuroendocrine neoplasms (NENs)","volume":"12","author":"Thomas","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.dld.2020.08.031_bib0145","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1200\/JCO.2018.36.15_suppl.4004","article-title":"A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN cancer research group (E2211)","volume":"36","author":"Kunz","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2020.08.031_bib0146","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000500135","article-title":"Activity and safety of standard and prolonged capecitabine\/temozolomide administration in patients with advanced neuroendocrine neoplasms","volume":"109","author":"Chatzellis","year":"2019","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2020.08.031_bib0147","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000335587","article-title":"ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors","volume":"95","author":"Falconi","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2020.08.031_bib0148","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1634\/theoncologist.2015-0476","article-title":"Gastroenteropancreatic well-differentiated grade 3 neuroendocrine tumors: review and position statement","volume":"21","author":"Coriat","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.dld.2020.08.031_bib0149","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1200\/JCO.2019.37.4_suppl.321","article-title":"Temozolomide in grade III neuroendocrine neoplasms (G3 NENs): A multicenter retrospective review","volume":"37","author":"Chan","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2020.08.031_bib0150","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.dld.2011.07.001","article-title":"Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma","volume":"43","author":"Brixi-Benmansour","year":"2011","journal-title":"Dig Liver Dis"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865820304539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865820304539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:14:15Z","timestamp":1761624855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865820304539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":150,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1590865820304539"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2020.08.031","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on gastroenteropancreatic neuroendocrine tumors","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2020.08.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}